|
Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers Clinical research trials and Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers. Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers clinical trial. Subjects often receive the most expert healthcare possible for their Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers  Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
For Condition: HIV Infection,Healthy
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This study will explore the responses of the immune system to HIV infection and changes in these responses over time. Healthy normal volunteers and HIV-infected patients 18 years of age or older may be eligible for this study. Participants will have a yearly medical examination, including blood tests to measure cell counts, evaluate kidney and liver function, and other lab tests as medically indicated. Women will have a blood or urine pregnancy test. Blood will be drawn from a needle in an arm vein one or more times during the course of the study. From 20 to 150 cc (4 to 30 teaspoonfuls) of blood will be collected at a time. No more than 450 cc (less than 1 pint) of blood will be drawn during any 6-week period. The blood may be used for the following tests: - Hepatitis and other viral screening-This may include screening for different types of viral liver infections, such as hepatitis A, B, C, D, E, or G; for cytomegalovirus (related to the herpes virus); and for varicella zoster virus (responsible for chicken pox in children and shingles in adults). - Genetic testing-DNA in blood cells may be examined for genetic mutations (physical or chemical changes) or deletions (missing pieces) that affect substances involved in the body's ability to mount an inflammatory immune response. Alterations in the genes for some of these substances have been shown to influence HIV infection. - HLA testing-HLA type is a genetic marker of the immune system. Determining HLA type is necessary in order to do certain research studies. Some HLA types have been associated with an increased risk of diseases like arthritis and other rheumatologic problems. HLA testing may be used to try to identify factors associated with the rate of progression of HIV disease or related conditions. Some blood collected in this study may be stored for future research. It will be labeled without identifying information.
Details: The Vaccine Research Center (VRC) is studying specific immune responses to HIV infection and other pathogens in order to characterize protective responses that can prevent new infection in uninfected individuals, as well as define those responses that lead to successful control of viral replication in persons already infected with the pathogen. We wish to define the specific human immune responses to HIV infection, other pathogens and vaccines using human peripheral blood mononuclear cells as a model.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: 1. Willing to be tested for HIV. Note: Subjects known to be HIV-infected will routinely have results of plasma HIV RNA obtained at or within 90 days of the enrollment visit recorded; volunteers believed to be HIV uninfected will usually have HIV ELISA (Western blot if needed) and/or HIV RNA within 28 days of the enrollment visit recorded. Test results do not have to be available before proceeding with enrollment. Consent to be tested is required, but the testing itself does not have to be completed if not needed by the research lab as subjects are eligible regardless of HIV status. 2. Age: 18 years of age or older. 3. Ability to provide informed consent EXCLUSION CRITERIA: 1. Refusal to consent to follow study site policy on partner notification (if newly diagnosed as HIV-positive while participating in this study). 2. Refusal to permit research blood specimens to be stored (frozen) for potential future studies. 3. Any medical condition that, in the opinion of the Principal Investigator, would make the subject inappropriate for protocol participation (such as coagulopathy or inadequate venous access). 4. Women known to be pregnant
Total Enrollment: 2000
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020066; 02-I-0066
Study Start Date: December 4, 2001
Record last reviewed: November 7, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00027482
Other Healthy Studies:
1. The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
2. Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine
3. Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan
4. EPOCH-Rituximab to Treat non-Hodgkin's Lymphoma in Patients with HIV Infection
5. Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children with HIV-1 Infection
Related Studies:
Other Healthy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
|
|
|
|
|
|
|
|
